VCP746 as an agonist for the adenosine A2A, A2B, and A3 receptors

被引：0
|
作者：
Sabbatini, A. R. [1 ,2 ,3 ]
Stoddart, L. [1 ,2 ,3 ]
Arruda, M. [1 ,2 ,3 ]
Hill, S. [1 ,2 ,3 ]
机构：
[1] Univ Nottingham, Sch Life Sci, Cell Signalling & Pharmacol Res Grp, Div Physiol Pharmacol & Neurosci, Nottingham, England
[2] Univ Birmingham, Ctr Membrane Proteins & Receptors COMPARE, Birmingham, W Midlands, England
[3] Univ Nottingham, The Midlands, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2019年 / 176卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
1953 P131
引用
收藏
页码：3030 / 3030
页数：1
相关论文
共 50 条
  • [1] The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling
    Vecchio, Elizabeth A.
    Chuo, Chung Hui
    Baltos, Jo-Anne
    Ford, Leigh
    Scammells, Peter J.
    Wang, Bing H.
    Christopoulos, Arthur
    White, Paul J.
    May, Lauren T.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2016, 117 : 46 - 56
  • [2] VCP746: a cardioprotective adenosine receptor agonist with minimal haemodynamic effects
    Chuo, C. H.
    May, L. T.
    Scammells, P.
    Wang, B. H.
    Krum, H.
    Kompa, A. R.
    White, P. J.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 776 - 776
  • [3] Heteromerization of adenosine A2A and A2B receptors
    Hinz, Sonja
    Seibt, Benjamin F.
    Schiedel, Anke C.
    Franco, Rafael
    Mueller, Christa E.
    [J]. PURINERGIC SIGNALLING, 2014, 10 (04) : 756 - 756
  • [4] Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
    Jamwal, Sumit
    Mittal, Ashish
    Kumar, Puneet
    Alhayani, Dana M.
    Al-Aboudi, Amal
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (26) : 2892 - 2905
  • [5] Renal ischemia reperfusion injury is reduced by the adenosine receptor agonist VCP746
    Seibt, Benjamin
    Lu, Bo
    Roberts, Veena
    Fang, Doreen
    Cowan, Peter
    Dwyer, Karen
    [J]. PURINERGIC SIGNALLING, 2014, 10 (04) : 682 - 683
  • [6] A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine
    De Filippo, Elisabetta
    Hinz, Sonja
    Pellizzari, Veronica
    Deganutti, Giuseppe
    El-Tayeb, Ali
    Navarro, Gemma
    Franco, Rafael
    Moro, Stefano
    Schiedel, Anke C.
    Mueller, Christa E.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2020, 172
  • [7] Heteromeric association of A2A and A2B adenosine receptors
    Feoktistov, I
    Ryzhov, S
    Goldstein, AE
    Biaggioni, I
    [J]. DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 574 - 574
  • [8] THE NOVEL ADENOSINE RECEPTOR AGONIST VCP746 REDUCES RENAL ISCHAEMIA REPERFUSION INJURY
    Benjamin, Seibt
    Bo, Lu
    Doreen, Fang
    Veena, Roberts
    Lauren, May
    Peter, Cowan
    Karen, Dwyer
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2014, 92 (08): : A20 - A20
  • [9] Screening of Non-Purine Ligands Binding to Adenosine Receptors A1, A2A, A2B, and A3
    Fiala, Mary M.
    Pattabiraman, Mahesh
    Hamilton, Luke
    Chandra, Surabhi
    [J]. FASEB JOURNAL, 2022, 36
  • [10] Modulation of adenosine A2A rceptor function by A2B receptors
    Feoktistov, I
    Ryzhov, S
    Goldstein, A
    Matafonov, A
    Maa, T
    Zeng, DW
    Belardinelli, L
    Biaggioni, I
    [J]. HYPERTENSION, 2003, 42 (03) : 391 - 391
12345